García-Donas et al63 studied dovitinib, a TKI that inhibits multiple targets including FGFR1/3, in a prospective, phase II trial of 17 patients with unresectable or metastatic ACC. The gene discussed is FGFR1; the disease is adrenal cortex carcinoma.